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ARTICLE
Streamlined ex vivo and in vivo genome editing in
mouse embryos using recombinant adeno-
associated viruses
Yeonsoo Yoon1, Dan Wang2,3, Phillip W.L. Tai 2,3, Joy Riley1, Guangping Gao2,3 & Jaime A. Rivera-Pérez 1
Recent advances using CRISPR-Cas9 approaches have dramatically enhanced the ease for
genetic manipulation in rodents. Notwithstanding, the methods to deliver nucleic acids into
pre-implantation embryos have hardly changed since the original description of mouse
transgenesis more than 30 years ago. Here we report a novel strategy to generate genetically
modiﬁed mice by transduction of CRISPR-Cas9 components into pre-implantation mouse
embryos via recombinant adeno-associated viruses (rAAVs). Using this approach, we efﬁ-
ciently generated a variety of targeted mutations in explanted embryos, including indel events
produced by non-homologous end joining and tailored mutations using homology-directed
repair. We also achieved gene modiﬁcation in vivo by direct delivery of rAAV particles into
the oviduct of pregnant females. Our approach greatly simpliﬁes the generation of genetically
modiﬁed mice and, more importantly, opens the door for streamlined gene editing in other
mammalian species.
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The advent of clustered regularly interspaced short palin-dromic repeats-Cas9 (CRISPR-Cas9) gene editing tech-nology has revolutionized gene targeting approaches and
greatly facilitates the generation of genetically modiﬁed mice1–3.
Despite the impressive advances in genome editing technology,
methods to deliver nucleic acids into pre-implantation embryos
has undergone minimal change. The conventional method,
developed more than 30 years ago, relies on microinjection of
zygotes to introduce RNA or DNA constructs4,5. This technique,
however, requires sophisticated micromanipulation equipment
that is operated by specially trained personnel6,7. A recently
developed method relies on electroporation to deliver CRISPR-
Cas9 components into zygotes8–14. This method has signiﬁcantly
improved the ability to generate gene-edited mice, yet it requires
specialized equipment to electroporate embryos or the oviduct of
pregnant females. An alternative approach is to use lentiviral
vectors15. Nonetheless, lentivirus-based vectors have been shown
to non-speciﬁcally integrate into the host genome, limiting their
utility as an effective tool for generating transgenic mice. Fur-
thermore, lentiviruses are unable to transduce pre-implantation
embryos unless they are injected into the perivitelline space or the
zona pellucida is removed prior to infection15,16.
Previous reports suggest that the zona pellucida is permeable to
several wild-type viruses including adeno-associated viruses17,18.
Here we explore the possibility of using recombinant adeno-
associated viruses (rAAVs) as vehicles for transducing intact
mouse zygotes to drive embryonic gene editing. AAV-based
vectors offer several advantages: they can lead to high levels of
transgene expression when delivered into host tissues, their
genomes are predominantly episomal once unpackaged in the
host cell, and they are rapidly diluted following cell division. In
addition, the relatively low genotoxicity proﬁle of rAAVs has also
been extensively exploited in human gene therapy applications19–
21. Our experiments indicate that multiple rAAV serotypes can
permeate the zona pellucida and transduce intact mouse embryos
at several pre-implantation stages independently of the mouse
strain used. We also show that genetically modiﬁed mice can be
generated after rAAV-driven transduction of zygotes with
CRISPR-Cas9 expression cassettes in explant culture and sub-
sequent transfer into pseudopregnant females. Moreover, we
provide proof-of-principle evidence that in vivo CRISPR-Cas9
gene editing can be achieved by the simple injection of rAAVs
into the oviduct of pregnant females. Our technology offers a
viable alternative to current techniques that is not dependent on
microinjection or electroporation of pre-implantation embryos.
Furthermore, our in vivo approach obviates the need to isolate
zygotes and the necessity to transfer treated embryos into pseu-
dopregnant females, greatly simplifying the generation of
genetically modiﬁed mice.
Results
Multiple rAAV serotypes transduce pre-implantation embryos.
To determine if rAAV vectors can permeate the zona pellucida,
we evaluated the ability of 14 rAAV serotypes to transduce
explanted pre-implantation embryos. Intact eight-cell morulae
were treated with a panel of rAAV serotypes packaged with an
identical enhanced green ﬂuorescent protein (EGFP) transgene
(rAAV.CB6-EGFP) at a dose of ~9.0 × 109 genome copies (GCs)
and evaluated after 1 day in culture. EGFP ﬂuorescence analysis
showed that all the serotypes tested were capable of transducing
intact morulae (Table 1, Supplementary Fig. 1). Serotype 6 was
one of the most effective AAVs, showing high levels of ﬂuores-
cence and embryo survival rate, and was therefore chosen for
subsequent experiments. We successfully utilized rAAV6.CB6-
EGFP to transduce zygotes from two inbred strains (C57BL/6NJ
and FVB/N) and one outbred strain (CD-1) with 100% efﬁciency
(Table 2). These results suggest that rAAVs can transduce intact
mouse embryos at multiple pre-implantation stages, irrespective
of mouse strain.
rAAV vectors can induce Cre-LoxP recombination in embryos.
To demonstrate the feasibility of rAAVs to mediate germline
transgenesis, we transduced R26mTmG heterozygous zygotes with
rAAV6.CB6-Cre (rAAV6-Cre) (Fig. 1a). The R26mTmG reporter
drives ubiquitous expression of membrane-bound tdTomato
ﬂuorescent protein. After Cre recombination, the tdTomato gene
is excised and the EGFP gene is expressed22 (Fig. 1b). After
treatment with rAAV6-Cre and 3 days in culture, the majority of
R26mTmG zygotes (32/38, 84%) underwent Cre recombination
(Fig. 1c, Table 3). In addition, transfer of treated embryos into
pseudopregnant females resulted in 37 out of 38 pups (97%)
showing green ﬂuorescence (Fig. 1d, Table 3, Supplementary
Fig. 2). We tested two of these mice, one male and one female, for
their ability to transmit the recombined transgene through the
germline (Fig. 1e). Both founder mice produced multiple green
ﬂuorescent pups after mating to wild-type CD-1 mice, at a fre-
quency close to the expected 50% Mendelian ratio (7/15 and 6/14,
respectively) (Fig. 1f). These results show that rAAV6 particles
can efﬁciently deliver Cre recombinase to zygotes to induce
genetic recombination that is germline transmissible.
rAAV vectors induce CRISPR-Cas9 genome editing in
embryos. To assess the ability of rAAV vectors to deliver Cas9
and single-guide RNA (sgRNA) transgenes into intact zygotes
and drive gene editing, we chose to target Tyrosinase (Tyr), a gene
essential for the synthesis of melanin. This strategy provides a
convenient way to visually screen for gene knockouts, since the
bi-allelic inactivation of Tyr by insertions and/or deletions
(indels) in embryos leads to albinism23–25. To express Cas9, we
used rAAV6.U1a-SpCas9 (rAAV6-Cas9), a vector containing the
Streptococcus pyogenes Cas9 gene driven by the mouse U1a
snRNA promoter. A second vector, rAAV6.U6-sgTyr-CB6-EGFP
(rAAV6-sgTyr), was used to drive the expression of a sgRNA
Table 1 Analysis of multiple rAAV serotypes for
transduction of morulae ex vivo
Serotypea Number of
treated
embryos
Number of
survivingb
embryos (%)
Number of
EGFP-
positive
embryos (%)
EGFP
intensityc
rAAV1 8 7 (87) 3 (43) +
rAAV2 9 9 (100) 9 (100) +
rAAV3b 9 4 (44) 1 (25) ++
rAAV4 10 9 (90) 2 (22) ++
rAAV5 9 6 (67) 2 (33) +
rAAV6 13 13 (100) 13 (100) ++++
rAAV6.2 11 7 (64) 7 (100) +++
rAAV7 16 14 (87) 14 (100) ++++
rAAV8 17 14 (82) 8 (57) ++
rAAV9 12 9 (75) 2 (22) ++
rAAVrh.39 12 11 (92) 7 (63) ++++
rAAVrh.43 15 13 (87) 13 (100) ++++
rAAVrh.8 10 7 (70) 4 (57) ++
rAAVrh.10 13 11 (85) 9 (81) +
no rAAV 81 74 (91) 0 (0) n/a
a Each rAAV serotype carries the same EGFP-expressing cassette
b Embryos that developed to compacted morula or blastocyst stage after 1 day in culture
c EGFP intensity was determined relative to non-treated control embryos and evaluated by two
observers
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under the control of the U6 promoter (Supplementary Fig. 3a).
The rAAV6-sgTyr vector also contains a cassette expressing EGFP
under the control of the CB6 promoter to monitor transduction
efﬁciency. We screened ﬁve sgRNAs targeting Tyr exon 1 and
chose the most effective one, which targets a site located between
the Tyrc-2J mutation23 and the classic Tyrc albino point mutation24,
for subsequent experiments (Supplementary Fig. 3b–e).
C57BL/6NJ zygotes were incubated with a 1:1 mixture of
rAAV6-Cas9 and rAAV6-sgTyr at three vector doses (6 × 109,
6 × 107, and 6 × 106 GCs) and cultured for 3 days until they
reached the compacted morula or blastocyst stages (Fig. 2a). The
prevalence of Tyr indel mutations in E3.5 embryos was
determined by T7EI nuclease analysis, TOPO sequencing, and
single-molecule real-time (SMRT) sequencing26 (Fig. 2b, Sup-
plementary Fig. 4a and 5). We found evidence of indels in all
experimental groups that was dosage related (Fig. 2b). Analysis
of three embryos treated with the highest dose (6 × 109 GCs)
revealed indels in all three embryos with a frequency of 100% or
≥99% indels within each embryo. At the lowest dose (6 × 106
GCs), two of three embryos showed evidence of indels.
However, the indel incidence in these embryos was only 23%
and 1.7%, indicating incomplete gene modiﬁcation. At the
intermediate dose (6 × 107 GCs), all three embryos contained
indels; one with an indel frequency of 100%, while the other two
had frequencies of 80.9% and 75.6%. Note that multiple indel
events exist in individual embryos, and that the variety of indels
appears to be more prominent in the intermediate dosage group
(upwards of eight indel types within a single embryo) than in the
highest or lowest dosage groups (Fig. 2b). These results suggest
that higher rAAV doses lead to indel events at earlier stages of
development, while lower doses lead to gene modiﬁcation at
later stages. In fact, the presence of eight different indels in two
of the embryos from the intermediate dose group suggests that
CRISPR-Cas9 activity was present at or beyond the four-cell
stage.
To gauge the ﬁdelity of rAAV delivery of CRISPR-Cas9
components, we also conducted experiments to generate indels
using microinjection. C57BL/6NJ zygotes were injected with
either a high-dose mixture (100 ng/μl Try sgRNA and 50 ng/μl
Cas9 RNA) or a low-dose mixture (5 ng/μl Try sgRNA and 6.67
ng/μl Cas9 RNA) of CRISPR-Cas9 reagents (Supplementary
Fig. 6). These concentrations were based on previous reports of
gene editing at the Tyrosinase locus12,25. Non-injected embryos
were used as negative controls. Embryos were cultured to
compacted morulae or blastocyst stages, and three embryos from
each group were subjected to whole-genome ampliﬁcation and
SMRT sequencing. All three embryos belonging to the high-dose
group showed a variety of indels that ranged from 2 to 13
different indel events per embryo (Supplementary Fig. 6). At the
lower concentration, only two of the embryos showed evidence of
indels, exhibiting 6 and 7 different indels. No evidence of indels
was found in non-injected control embryos. These experiments
reveal a variety of mutations per embryo indicative of mosaicism
and suggest that rAAV-delivery and microinjection lead to
similar genome editing outcomes.
Generation of gene-edited mice after rAAV exposure ex vivo.
To determine the ability of rAAV-CRISPR-Cas9-treated embryos
to develop to birth, transduced zygotes were cultured overnight
and those that advanced to the two-cell stage were transferred
into pseudopregnant recipients. Embryos at E16.5 and newborns
were assessed for the absence of eye pigmentation (Fig. 2c); 1-
week old pups or older were also evaluated for albino coat color.
The frequency of indels (deﬁned as the percentage of phenoty-
pically albino and mosaic animals) was 100% in embryos and
newborns for the 6 × 109 GC dose group (Table 4). Corre-
spondingly, all of the pups generated with this dose were albino,
suggesting bi-allelic targeting of Tyrosinase (Fig. 2d, Table 4 and
Supplementary Fig. 4b, c). Zygotes treated with 6 × 108 GCs
resulted in live births with 100% indel frequency, among which
80% were albino (Fig. 2e and Table 4). The editing frequency
dropped to 25% for E16.5 embryos and 20% for newborns at 6 ×
107 GCs. No edited animals were detected from the 6 × 106 GC
treatment group (Table 4). These results are consistent with the
sequencing data obtained in E3.5 embryos (Fig. 2b), supporting
the notion that gene editing efﬁciency is rAAV dose dependent.
To test for germline transmission of Tyr indel alleles, one
albino male and three albino females derived from the 6 × 109 GC
dose group were mated to albino CD-1 mice (Tyrc/c) (Fig. 2f). In
these crosses, we only obtained albino pups from all of the tested
founders, indicating successful germline transmission (Fig. 2g).
These results show that gene modiﬁcation mediated by rAAV
delivery of Cas9 and sgRNA transgenes is highly efﬁcient and can
lead to germline transmission.
It has been previously shown that the rAAV genome can
integrate into the host genome following in vivo delivery in adult
mice27,28. To analyze animals for rAAV genome integration, we
performed PCR analysis to detect Cas9 and EGFP genes using tail
snip DNA from pups generated from transduced zygotes. The
majority of samples (44/45) were negative, suggesting that
episomal rAAV genomes present in zygotes were diluted during
development and were eventually lost. However, one pup (1/45)
was positive for both the Cas9 and EGFP genes, indicating rAAV
genome integration (Supplementary Fig. 7a). We reasoned that
such rAAV genome integration would most likely occur at the
Cas9 on-target cleavage site, which was conﬁrmed by further
analysis with a targeted PCR approach (Supplementary Fig. 7b, c).
We additionally assessed the genomes of whole E16.5 embryos for
genome-wide rAAV integration using a strategy comprising
linear ampliﬁcation mediated-PCR (LAM-PCR) and SMRT
sequencing. No integration events were detected in rAAV6-
Cas9 control embryos or in the rAAV6-Cas9+rAAV6-sgTyr
experimental group (n = 3) (Supplementary Fig. 8). Taken
Table 2 Transduction efﬁciency of zygotes from different strains of mice with rAAV6-EGFP
Genetic background Treatment Number of treated zygotes Number of survivingb embryos (%) Number of EGFP-positive embryos (%)
C57BL/6J rAAV6-EGFPa 30 30 (100) 30 (100)
no rAAV 8 5 (63) 0 (0)
FVB/N rAAV6-EGFP 24 16 (67) 16 (100)
no rAAV 12 11 (92) 0 (0)
CD-1 rAAV6-EGFP 9 9 (100) 9 (100)
no rAAV 8 7 (88) 0 (0)
a Experimental embryos were exposed to viral particles for 5–6 h
b Embryos that developed to compacted morula or blastocyst stage after 3 days in culture
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Fig. 1 Recombinant AAV vectors can induce Cre-LoxP recombination. a Schematic representation of the strategy to induce Cre-LoxP recombination using
rAAVs. R26mTmG heterozygous zygotes derived from breeding R26mTmG homozygous and wild-type mice were placed in a drop of KSOM media containing
rAAV particles, rinsed, cultured in KSOM, and analyzed for ﬂuorescence after 3 days in culture or were transferred into pseudopregnant females after 1 day
in culture and allowed to develop to term. b Schematic representation of the R26mTmG ﬂuorescence reporter. R26mTmG embryos express the membrane-
targeted tdTomato gene (mT) and ﬂuoresce red. Cre-mediated recombination drives expression of membrane-targeted EGFP (mG), making recombined
cells ﬂuoresce green. c Fluorescence analysis of compacted morulae transduced with rAAV6-Cre. Maternal mT protein is present in both non-treated (top
row) and treated (bottom row) embryos, making them ﬂuoresce red. Transduction with rAAV6-Cre leads to green ﬂuorescent embryos (bottom row),
indicative of Cre-mediated recombination. Inset is a merged image of the embryo marked by arrows to highlight mosaicism evident by the absence of green
ﬂuorescence in some cells. Scale bar equals 50 μm. d Fluorescence analysis of pups derived from zygotes transduced with rAAV6-Cre in culture and
transferred into pseudopregnant females. Two pups show complete Cre-lox recombination (1 and 2), two are mosaic (3 and 4), and one (5) did not
undergo recombination. e Schematic representation of the strategy to test for germline transmission of the recombined R26mG allele obtained after rAAV6-
Cre treatment of R26mTmG/+ zygotes in culture. f R26mG/+ mother and her offspring derived from a cross to a wild-type male; two R26mG/+ pups are visible
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Table 3 Ex vivo Cre recombination after transduction of R26mTmG zygotes with rAAV6-Cre
Number of treated
zygotes
Time of analysis Number of surviving embryosa
or pups (%)
Number of EGFP-positive
embryos or pups (%)
Number of mosaic embryos or
pups (%)
40 E3.5 38 (95) 32 (84) 5 (16)
74 P2b 38 (51) 37 (97) 15 (37)
a Embryos that developed to compacted morula or blastocysts after 3 days in culture
b Embryos were cultured overnight, transferred into pseudopregnant females and analyzed at postnatal day 2
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together, these results suggest that rAAV genome integration is a
rare event in founder animals and can be identiﬁed by PCR-based
genotyping.
Small-scale preparations of rAAVs lead to gene-edited mice.
The rAAV transduction experiments shown above were con-
ducted using a traditional large-scale rAAV vector production
procedure that requires specialized equipment and expertise29.
However, we also achieved high-indel frequencies using a sim-
pliﬁed small-scale protocol30 that can be adapted to standard
molecular biology laboratories. This simpliﬁed protocol requires
only a ﬁfth of the producer cells required for large-scale pro-
duction and a fraction of the rAAV puriﬁcation time. The single-
day puriﬁcation procedure utilizes iodixanol gradient cen-
trifugation and affordable puriﬁcation columns, whereas the
large-scale puriﬁcation involves multiple runs of CsCl sedi-
mentation followed by dialysis, and takes ~5 days to complete
(Supplementary Fig. 9a). Using this small-scale protocol, we were
able to produce rAAV vector titers (4.6 × 1011 GC/ml and 1.6 ×
1012 GC/ml for sgTyr and sgFah, respectively), sufﬁcient to gen-
erate indels in the Tyr and the Fumarylacetoacetate hydrolase
(Fah) gene loci with 100% frequency (Supplementary Fig. 9b–e).
Thus, genome editing can be efﬁciently achieved using small-scale
preparation of rAAV vectors, and can be applied to more than
one genomic locus.
rAAV vectors generate precise genetic modiﬁcations via HDR.
An important feature of genome editing is the ability to generate
precise genetic changes. Therefore, we tested the capacity for
rAAV vectors to deliver components for Cas9-mediated homol-
ogy-directed repair (HDR). To achieve this goal, we designed two
rAAV genomes as HDR donors for use in combination with the
rAAV6-Cas9 and rAAV6-sgTyr vectors. The donor vectors carry
a DNA construct that consists of ~800 bp homology arms on
either side of the sgTyr target site (Fig. 3a–c). A single-nucleotide
transversion (SNT) strategy was used to generate a premature
stop codon in Tyr for an albino phenotype (Fig. 3b). We also
designed a donor vector to introduce a 771 bp blue ﬂuorescent
protein (BFP) cassette containing a porcine teschovirus-1 2A
peptide and a stop codon (P2A-BFP-TAA) (Fig. 3c). We incu-
bated zygotes with these three vectors and cultured them for
3 days until the compacted morulae or blastocyst stages for gene
editing analysis. DNA obtained from SNT embryos was subjected
to PCR, TOPO cloning, and Sanger sequencing to determine the
frequency of the G to T transversion. We found that rAAV
transduction resulted in 40% SNT-positive embryos (6/15)
(Fig. 3d). Among the sequenced TOPO clones, the HDR
frequency in individual SNT-positive embryos ranged from 8% to
45% (Fig. 3e). We also identiﬁed one live-born (1/20) that carried
68% SNT Tyr alleles (Fig. 3e). Mating this SNT-positive male with
a CD-1 female resulted in 8 out of 15 (53%) pups carrying the
SNT allele (Supplementary Fig. 10), indicating germline
transmission.
The insertion of the BFP cassette was determined using PCR,
and the BFP insertion was present in as high as 57% of embryos,
depending on the vector dosage (Fig. 3d–f). We were also able to
generate two pups that carried the BFP insertion (2/24) as
determined by PCR analysis of tail snips and ear punches. One
male was assessed for germline transmission by crossing to wild-
type females. We found that 35% (9/26) of the F1 pups obtained
from these crosses inherited the BFP insertion. These data
demonstrate that infecting zygotes with rAAV vectors can induce
HDR-mediated gene editing in embryos to generate genetically
modiﬁed mice that can transmit the HDR allele to the next
generation.
rAAV-CRISPR-Cas9 vectors produce gene-edited mice in vivo.
The ability of rAAV to mediate genetic modiﬁcation of intact pre-
implantation embryos ex vivo prompted the question of whether
injection of viral particles into the oviduct of pregnant females
could also result in gene modiﬁcation of pre-implantation
embryos in vivo. At E0.5, zygotes are located in the ampulla, a
swollen region of the oviduct where fertilization occurs6. There-
fore, we assessed the feasibility of in vivo embryonic gene mod-
iﬁcation by injecting rAAV6-Cas9 and rAAV6-sgTyr vectors
directly into the ampulla of E0.5 C57BL/6NJ females mated with
C57BL/6NJ males (Fig. 4a, b). We injected 1.5 to 3 μl of a solution
containing a 1:1 mixture of the two vectors and Chicago sky blue
dye (to visualize the site of injection) into the ampulla of a single
oviduct in each female. We obtained 29 pups from 5 litters, and
identiﬁed 3 pups with indels from 3 litters (Fig. 4c, d and
Table 5). Gene modiﬁcation was conﬁrmed by SMRT sequencing
(Fig. 4d). All three founder animals with indels (one male and
two females) were tested for germline transmission by mating
them with CD-1 albino mice and all three generated albino off-
spring indicating germline transmission (Fig. 4e). In summary, 3
out of 29 mice derived from in vivo embryonic transduction with
rAAV vectors showed gene modiﬁcation at the Tyr locus, a fre-
quency of ~10% (Table 5). However, we note that because only
one oviduct was injected per female, the gene editing frequency is
likely an underrepresentation of the actual procedure efﬁciency.
These data suggest that rAAV particles can access pre-
implantation embryos in the oviduct to deliver CRISPR-Cas9
components for genome modiﬁcation in vivo.
Fig. 2 Gene editing in intact pre-implantation embryos transduced with rAAV vectors. a Schematic representation of the strategy to transduce C57BL/6NJ
zygotes with rAAV vectors designed to target the Tyrosinase (Tyr) locus. Zygotes were placed in KSOM containing rAAV6-Cas9 and rAAV6-sgTyr vectors,
rinsed, cultured at 37 °C for 3 days, and analyzed for Tyr gene editing at compacted morula or blastocyst stages. Alternatively, they were cultured overnight
and transferred at the 2-cell stage into the oviducts of E0.5 pseudopregnant females. Transferred embryos were assessed for eye pigmentation at E16.5, or
allowed to develop to birth and assessed for eye and coat color pigmentation. b Stacked histogram showing the percentage distribution of indel-type
frequencies among four rAAV-dosage groups . Alterations indicate base replacements; large deletions are deﬁned as removal of >20 bases and compound
mutations are combinations of insertions, deletions, and/or alterations. c Analysis of eye pigmentation in E16.5 embryos transduced with rAAV6-Cas9 only
(left panel) and both rAAV6-Cas9 and rAAV6-sgTyr (right panel). Arrow in the right panel indicates the location of the eye in a transduced albino embryo.
d Albino litter generated after transduction of C57BL/6NJ zygotes with CRISPR-Cas9 rAAV vectors at 6 × 109 GC dose. Shaved area on female indicates
site of embryo transfer surgery. e A representative litter obtained after transduction of C57BL/6NJ zygotes with CRISPR-Cas9 rAAV vectors at 6 × 108 GC
dose. Three out of ﬁve pups are albino and two are mosaic as revealed by the variegated coat color pattern. f Schematic representation of the strategy to
test germline transmission of CRISPR-Cas9-induced alleles of Tyr. Tyr-edited albino mice were mated with albino CD-1 (Tyrc/c) animals and the offspring
were assessed for the presence of albino coat color. g Litter derived from Tyr-edited albino male crossed with a CD-1 female. All pups are albino indicating
germline transmission
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Discussion
There are several important ramiﬁcations for our study. First, to
our knowledge, this is the ﬁrst time that rAAV-based vectors have
been used to transduce intact pre-implantation embryos in either
ex vivo or in vivo in mice. Second, the ability to transduce
embryos without removing the zona pellucida is a major
advantage over using lentiviral vectors, which requires the
removal of the zona pellucida, or microinjection into the perivi-
telline space15,16. Similarly, it is an advantage over electroporation
techniques that require thinning of the zona pellucida with
Tyrode’s solution to facilitate the penetration of the CRISPR-Cas9
reagents into the zygote11–13. Third, the use of rAAV vectors also
enables the generation of genetically modiﬁed mice without
relying on techniques that require sophisticated devices, such as
pronuclear injection. Fourth, transduction with rAAV vectors
allows for easy scale-up to modify large batches of embryos.
Furthermore, we demonstrate that rAAVs can transduce pre-
implantation embryos at the eight-cell stage. This is of particular
relevance, since blastomeres at this stage are totipotent and offer
an alternative to transducing zygotes31,32.
Our technique offers an alternative approach that expands the
toolbox for animal modeling. Using pronuclear injection, Yen
et al.25 reported bi-allelic Tyr targeting in C57BL/6N
zygotes (1 albino pup out of 33) using two sgRNAs while Chen
et al.12 generated 88% albino mice by electroporating zygotes with
SpCas9 protein and a single sgRNA targeting a Tyr site adjacent to
ours. We also generated edits at the Tyr locus using pronuclear
injection based on microinjection conditions reported in these two
studies. Our results revealed high levels of indels in 5 out of 6
embryos and the presence of multiple indel events that ranged
from 2 to 13 mutations per embryo. Our experiments using
rAAVs led to 80% and 100% albino pups using doses of 6 × 108
and 6 × 109 GC rAAVs, respectively, suggesting comparable gene
editing levels. However, it should be noted that, although the
studies compared here share a common gene target in the same
genetic strain of mice (the Tyr locus in C57BL/6 embryos), it is
still difﬁcult to make a fair comparison since multiple variables are
at play. The experiments of Chen et al.12 provide a good example.
These authors reported 88% bi-allelic targeting at the Tyr locus;
however, much lower bi-allelic targeting was found at three other
loci (Cdh1, 0%; Kif1, 14%; and Cdk8, 14%)12. These results suggest
that factors other than the delivery method, such as differences in
sgRNA choice, genomic environment, or inability to control the
amount of CRISPR-Cas9 components that reach a zygote, can play
roles in determining the ﬁnal gene editing frequency in mouse
embryos. Notably, we were able to achieve high targeting efﬁ-
ciency in Tyr as well as the Fah locus, supporting the robustness of
our technique.
The occurrence of mosaicism in individual Cas9-edited foun-
der animals appears to be a common phenomenon in genome
editing strategies12,25,33, including ours. In pronuclear experi-
ments, Yen et al.25 found that the majority of albino and mosaic
founder animals harbored two or more Tyr mutant alleles25.
Mosaicism was also found at the Tyr locus in electroporation
studies12 and we also found a high level of mosaicism in our Tyr
pronuclear injection experiments. SMRT sequencing analysis
conducted in our rAAV experiments showed that levels of
mosaicism appear to depend on the concentration of the rAAV
dose used, with the lower dose (6 × 107 GCs) resulting in a rela-
tively high level of mosaicism. Interestingly, we observed that all
three embryos of the high-dose group (6 × 109 GCs), as well as
two out of three embryos treated with the lower 6 × 107 GC dose,
harbored a dominant allele that accounted for about 50% of the
total number of mutated alleles. Segregating such predominant
mutant alleles in F1 animals is feasible following common
breeding practices. Although mosaicism can be perceived as a
negative outcome in gene editing experiments in mice, mosaic
animals pose advantages under certain circumstances. For
example, they can be useful in the establishment of mouse lines
harboring lethal alleles10. This is an important point since it is
estimated that 35.7% of knockout mice are lethal or sub-lethal
before reaching weaning age34. Mosaics are also useful since they
harbor a variety of mutations in the same locus, a valuable asset
that can allow better dissection of gene function.
We detected one pup harboring rAAV integration at the Cas9
on-target cut site during analysis of 45 pups by performing PCR.
Using a genome-wide analysis based on LAM-PCR, we did not
detect rAAV genome integration in three E16.5 embryos tested.
Therefore, rAAV integration appears to be a rare event that may
be facilitated by Cas9-mediated DNA breaks. Intriguingly, this
phenomenon could be exploited in homology-independent tar-
geted integration events, as recently described35. Regardless,
unwanted rAAV integration events at the target site can be cir-
cumvented by analyzing multiple independent mouse lines gen-
erated during the genome editing process. In addition, random
rAAV integration events can be eliminated by consecutive
breeding with wild-type animals.
Our results show that rAAVs can be used to introduce com-
ponents for Cas9-mediated homology-directed repair. This is a
major achievement that allows for the generation of speciﬁc
genetic changes at precise genomic loci. Using traditional pro-
nuclear injection techniques, Mizuno et al.36 generated a point
mutation to mimic the Tyrc-2j mutation using HDR via an oligo
DNA donor; this led to 18% of pups carrying the HDR allele.
Chen and co-workers also used oligo donor templates to generate
point mutations at a site adjacent to our Tyr targeting site, with a
frequency of 42%, or insertion of a 42 bp V5 tag at the Sox2 locus
with a frequency of 31%. In our study, introducing a point
mutation in Tyr using a rAAV donor vector led to a frequency of
40% in E3.5 embryos. Using a different donor vector, we were
Table 4 Ex vivo gene editing after transduction of C57BL/6NJ zygotes with CRISPR-Cas9 rAAV vectors
rAAV dosage
(GCs)
Number of zygotes
transferred
Time of
analysis
Number of embryos or pups
recovered (%)
Tyr-edited embryos or
pups (albino)a
Tyr editing frequency
(%)
6 × 109 17 E16.5 7 (41) 7 (6) 100
28 P10 5 (18) 5 (5) 100
6 × 108 17 E16.5 9 (53) 7 (7) 78b
46 P10 10 (22) 10 (8) 100
6 × 107 35 E16.5 16 (48) 4 (0) 25
83 P10 25 (30) 5 (3) 20
6 × 106 16 P10 6 (38) 0 0
0 55 P10 19 (35) 0 0
a Gene editing evidence obtained by assessing eye pigmentation in embryos or coat color in pups and by genome analysis
b Two pigmented embryos were not assessed for gene editing at the genomic level
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Fig. 3 Recombinant AAV vectors can mediate homology-directed repair (HDR). a Schematic representation of the Tyr locus and location of sgRNA in exon
1. The orange and red lines mark the initiation and termination codons respectively. The green line indicates the location of the sgRNA used to target Tyr. b
Strategy to introduce a premature stop codon in the Tyr locus using HDR. The 5′ and 3′ homology arms are marked by a thick line. A G to T nucleotide
transversion in the PAM sequence converts a glycine codon (GGA) into a stop codon (TGA) disrupting translation of Tyr. Arrows indicate binding sites of
the primers used in PCR-TOPO sequencing. c Strategy to insert the blue ﬂuorescent protein (BFP) gene into the Tyr locus using HDR. Brown and purple
arrows depict the binding sites of PCR primers used to conﬁrm the insertion of BFP into Tyr locus. P2A, Porcine teschovirus-1 2A peptide; TAA, Stop codon.
d Histogram showing the frequency of single-nucleotide transversion and BFP insertion by HDR using two different mixtures of rAAV vectors. e Analysis of
single-nucleotide transversion in individual embryos or pups using PCR-TOPO sequencing. Each bar represents an individual sample. For pups, only DNA
from tail snips and ear punches was analyzed. f Conﬁrmation of BFP insertion using PCR. Four out of seven E3.5 embryos tested showed correct insertion of
BFP into the Tyr locus. The top panel shows ampliﬁcation of the 5′-junction of the targeted Tyr locus using a forward primer that binds to genomic DNA
upstream of the homology region and a reverse primer that binds to the BFP gene as shown in (c). The bottom panel shows ampliﬁcation of the 3′-junction
of the Tyr-edited allele using a forward primer that binds to the BFP gene and a reverse primer that binds to genomic DNA downstream of the homology
region
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able to introduce a 771 bp BFP cassette into the Tyr locus with a
frequency in embryos as high as 57%. Surprisingly, a lower per-
centage of live-born animals carried such HDR events (1/20 and
2/24 for the point mutation and BFP insertion, respectively). One
possible explanation is that these founder mice are mosaic and
that the analysis of tail snips and ear punches may have led to an
underestimation of HDR in the whole organism. This would not
be the case in embryos where the whole animal was subjected to
analysis. Another explanation is that HDR events present in
progenitors of extra-embryonic tissues that are detected in the
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Fig. 4 In vivo gene editing after oviduct injection with rAAV vectors. a Schematic representation of the strategy to induce in vivo gene editing of the Tyr
locus. rAAV vectors carrying SpCas9 and sgTyr expression constructs were injected directly into the oviduct of plugged C57BL/6NJ females mated to
C57BL/6NJ males. Coat color was assessed in the offspring. b Close-up view of the reproductive tract showing the process of in vivo delivery of rAAVs into
the ampulla of the oviduct. The rAAV injection solution contains a blue tracer dye that is visible at the tip of the glass micropipette. A small pool of the
injected solution is evident inside the ampulla. U uterus, Ov oviduct, O ovary. c Representative litter born after in vivo gene editing of Tyr. One out of eight
pups born was albino. d Stacked histogram showing the percentage distribution of indel-type frequencies in two albino (1 and 2) and two black (3 and 4)
pups by SMRT sequencing. Three C57BL/6NJ control samples (C1–C3) were included in the analysis. Alterations indicate base replacements; compound
mutations are combinations of insertions, deletions, and/or alterations. The yellow area in sample C3 is likely the product of sequencing error. e Litter
derived from Tyr-edited albino male crossed with a CD-1 female. All pups are albino indicating germline transmission
Table 5 In vivo gene editing after injection of rAAVs into the oviduct of pregnant females
Vector injecteda Number of litters Number of pupsb Tyr-edited pups (albino)c Tyr editing frequency (%)d
rAAV6-SpCas9+rAAV6-sgTyr 5 29 3 (2) 10
a Only left oviduct was injected
b Includes pups from injected and non-injected oviducts
c Gene editing evidence determined by assessing coat color and sequence analysis
d Approximate frequency; includes pups from treated and non-treated oviducts
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analysis of pre-implantation stage embryos will not be present in
live borns. Nevertheless, we successfully generated F1 animals
carrying the HDR alleles following a common breeding scheme,
demonstrating that our approach is a viable alternative for gen-
erating HDR-mediated genetic modiﬁcations in mouse embryos
for animal modeling.
We provide proof-of-concept demonstration that embryos can
be genetically modiﬁed in vivo by direct delivery of rAAV par-
ticles into the oviduct. This is a tantalizing discovery that could
further facilitate gene editing in mice and other mammalian
species, since it will no longer require embryo isolation, micro-
injection, embryo culture, and transfer into pseudopregnant
females. Oviduct injections are also simpler than performing
oviduct or uterine transfers of embryos, a requirement for gen-
erating genetically modiﬁed mice using standard approaches.
With the rapid development of modiﬁed CRISPR-Cas9 systems, it
is possible to further enhance the efﬁciency and precision for our
in vivo genome editing strategy. For example, a single vector
platform expressing both a shorter version of Cas9 and target-
speciﬁc sgRNA can be used to further simplify and improve our
embryonic gene editing approach1–3,37. It may also be possible to
combine our technology with multiple innovative approaches
such as the use of mice constitutively expressing Cas938 or base
editing approaches to modify single bases in the genome39.
Finally, one exciting possibility is the use of rAAVs to introduce
large fragments of DNA into the genome by sequential homo-
logous recombination as recently described40. This is a clever
achievement that signiﬁcantly ampliﬁes the potential of rAAV in
genome editing studies in embryos.
Methods
Mouse strains and embryo collection. All animal experiments were conducted
under the guidance of the institutional animal care and use committee of the
University of Massachusetts Medical School. C57BL/6NJ (Stock No. 005304), FVB/
NJ (Stock No. 001800), and R26mTmG (Gt(ROSA)26Sor tm4(ACTB-tdTomato,-EGFP)Luo,
Stock No. 007676) mice were obtained from The Jackson Laboratory. CD-1 mice
were obtained from Charles River Laboratories (Strain code 022). R26mTmG mice
were maintained in a CD-1 outbred genetic background. All animals were main-
tained in a 12 h light cycle. The middle of the light cycle of the day when a mating
plug was observed was considered embryonic day 0.5 (E0.5) of gestation. Zygotes
were collected at E0.5 by tearing the ampulla with forceps and incubation in M2
medium containing hyaluronidase to remove cumulus cells. Eight-cell morulae
were collected by ﬂushing the oviduct with M2 medium at E2.5.
Recombinant AAV vectors. All the rAAV serotypes used in morulae experiments
contained the same rAAV.CB6-EGFP construct. The EGFP expression vector
consists of the CB6 promoter (cytomegalovirus enhancer fused to the chicken β-
actin promoter) driving EGFP expression41. rAAV6.CB6-Cre carries the Cre
recombinase gene driven by the CB6 promoter. In rAAV6.U1a-SpCas9, expression
of the S. pyogenes Cas9 (SpCas9) is driven by the ubiquitous U1a promoter42.
scAAV6.U6-sgRNA.CB6-EGFP carries two expression cassettes, one expressing the
sgRNA targeting the Tyrosinase (Tyr) gene or the Fah gene under the U6 promoter,
and the other expressing EGFP under the CB6 promoter.
Recombinant AAV vector production and puriﬁcation. Recombinant AAV
vectors were produced by calcium phosphate triple transfection of plasmids in
HEK293 cells. For large-scale preparation, approximately 8.5 × 108 cells were
transfected. rAAV was puriﬁed by two rounds of CsCl sedimentation followed by
dialysis29, which took a period of 7 days. For small-scale preparation, approxi-
mately 1.7 × 108 cells were transfected. rAAVs were puriﬁed using iodixanol gra-
dient centrifugation30. Brieﬂy, HEK293 cells were detached by vigorously shaking
the culture vessel. The cell suspension underwent three cycles of freezing (dry ice/
ethanol bath) and thawing (37 °C water bath) for cell lysis and subsequent ben-
zonase treatment. After centrifugation, the supernatant was transferred to an
ultracentrifugation tube containing a discontinued gradient of 15, 25, 40, and 60%
of iodixanol (Accurate Chemical, Cat. No. AN1114542). Gradient centrifugation
was carried out at 504,000 × g for 70 min at 20 °C. The rAAV vectors at the 40–60%
interface were collected and subjected to desalting using a Zeba column (Thermo
Fisher Scientiﬁc, Cat. No. 89894) and concentrated using an Amicon Filter Unit
(EMD Millipore, Cat. No. UFC910024). The entire procedure can be ﬁnished
within 1 day. All rAAV vectors were titrated by droplet digital PCR (ddCPR, Bio-
Rad) for genomes and silver staining of capsid proteins.
Transduction of pre-implantation embryos in explant culture. Zygotes or 8-cell
morulae were incubated in 10 or 15 μl drops of KSOM (Potassium-Supplemented
Simplex Optimized Medium, Millipore, Cat. No. MR-020P-5F) containing the
following rAAV vectors: scAAV.CB6-EGFP (9.0 × 109 GCs); scAAV6.CB6-EGFP
(2.25 × 109 GCs); rAAV6.CB6-Cre (3.75 × 109 GCs); rAAV6.U1a-SpCas9 (3.0 × 109
GCs, 1.5 × 109 GCs, 3.0 × 108 GCs, 3.0 × 107 GCs, or 3.0 × 106 GCs); scAAV6.U6-
sgTyr.CB6-EGFP (3.0 × 109 GCs, 1.5 × 109 GCs, 3.0 × 108 GCs, 3.0 × 107 GCs, or
3.0 × 106 GCs); rAAV6.TyrDonorWithSNT.CB6-mCherry (3.0 × 109 GCs); rAAV6.
TyrDonorWithP2A-BFP.CB6-mCherry (3.0 × 109 GCs); scAAV6.U6-sgFahExon.
CB6-EGFP (3.0 × 109 GCs, 3.0 × 108 GCs) for 5–6 h. Drops were placed in 35 mm
plates under mineral oil (Sigma, M8410) at 37 °C in a tissue culture incubator
containing 5% CO2 and 5% O2. After the incubation period, the embryos were
rinsed once in M2 medium and transferred to fresh KSOM for subsequent culture.
Zygotes were cultured for 3 days and morulae for 1 day to reach compacted morula
or blastocyst stages. To develop transduced zygotes to term, embryos were cultured
overnight and those that advanced to the two-cell stage were transferred into the
oviduct of E0.5 pseudopregnant CD-1 females. Operated females were allowed to
carry the embryos to term or were euthanized at E16.5 to obtain embryos for
analysis.
Transduction of zygotes in vivo using rAAVs. Recombinant AAVs were injected
into the oviduct of females on the day when the mating plug was observed (E0.5).
Only the oviduct of the left horn was injected. The untreated right horn served as a
hedge for pregnancy loss in the case of embryo lethality on the treated side of the
oviduct. The volume injected ranged from 1.5 to 3 μl and was injected using glass
needles with tip diameter of 15–30 μm. The tracer dye Chicago sky blue (0.1%)
(Sigma Cat. No. C8679) was used to track the site of injection. To generate indels
using the CRISPR-Cas9 system, we injected E0.5 C57BL/6NJ females mated to
males of the same strain. A 1:1 mixture of rAAV6.U1a-SpCas9 and scAAV6.U6-
sgTyr.CB6-EGFP (4.0 × 109 GCs/μl each) was injected into the ampulla of the left
oviduct. The right oviduct was not injected. Operated females were allowed to carry
the embryos to term.
Generation of gene-edited embryos using pronuclear injection. Zygotes derived
from crosses between C57BL/6J mice were collected at E0.5 as described above. .
The male pronucleus was microinjected using a high (100 ng/μl Tyr sgRNA and 50
ng/μl Cas9 RNA) or a low (5 ng/μl Tyr sgRNA and 6.67 ng/μl Cas9 RNA) dose.
Injected zygotes were cultured overnight in KSOM media for 3 days until they
reached the compacted morula or blastocyst stage. Embryos were then processed
for whole-genome ampliﬁcation and SMRT sequencing as described below.
Analysis of embryos or pups transduced with rAAV6.CB6-Cre. To determine
Cre-mediated recombination in transduced R26mTmG/+ embryos, EGFP ﬂuores-
cence was assessed in morulae or blastocysts. Fluorescence was assessed qualita-
tively relative to non-transduced controls using an inverted Leica microscope
(DMI4000) equipped with epiﬂuorescence. Pups were screened at postnatal day 1
or 2 (P1 or P2) for the presence of EGFP (mG) or tdTomato (mT) ﬂuorescence
using a dual ﬂuorescent protein ﬂashlight (Nightsea, Bedford, MA. USA).
Fluorescence imaging of adult tissue cryosections. Mice were anesthetized by
isoﬂurane, and transcardially perfused with ice-cold phosphate-buffered saline
followed by 4% paraformaldehyde (PFA). Organs were dissected and post-ﬁxed in
4% PFA overnight. Organs were then cryopreserved in 30% sucrose overnight,
embedded in Tissue-Tek OCT compound (Sakura Finetek), and sectioned at a
Table 6 List of primers used in PCR analysis
Target Orientation Sequence
Tyr Forward 5′-TTGTTGGCAAAAGAATGCTG-3′
Reverse 5′-GCTTCATGGGCAAAATCAAT-3′
Tyr G to T
transversion
Forward 5′-TGAAGCAGTTCACCAAAATAAC-3′
Reverse 5′-CTGTTTGAGAGTCAGCAACG-3′
BFP/Tyr 5′
junction
Forward 5′-TGAAGCAGTTCACCAAAATAAC-3′
Reverse 5′-GCGAGCTGATTAAGGAGAAC-3′
BFP/Tyr 3′
junction
Forward 5′-GCTAAGAACCTCAAGATGCC-3′
Reverse 5′-CGTTGCTGACTCTCAAACAG-3′
Fah Forward 5′-ACCCCTGTGTGATAGACCAC-3′
Reverse 5′-CATGGGCTGCTATTTGTGGC-3′
SpCas9 Forward 5′-CTGAGCAAGGACACCTACGA-3′
Reverse 5′-CTCGGTGTTCACTCTCAGGA-3′
EGFP Forward 5′-CTGAAGTTCATCTGCACCACC-3′
Reverse 5′-ATGCCGTTCTTCTGCTTGTCG-3′
Integration of
rAAV
Forward 5′-AGGAACCCCTAGTGATGGAGT-3′
Reverse 5′-GCTTCATGGGCAAAATCAAT-3′
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thickness of 8 µm in a cryostat. Tissue sections were mounted with vectashield
mounting medium containing DAPI (Vector Labs, H1200), and imaged using an
upright ﬂuorescence microscope (Leica DM5500B).
Analysis of embryos or pups transduced with rAAVs. To determine the gen-
otype of edited Tyr alleles, individual compacted morulae, blastocysts, or E16.5
embryos were collected and subjected to SMRT sequencing analysis or T7EI
nuclease assay (see below). The phenotype was assessed at E16.5 or after birth. The
levels of eye pigmentation in E16.5 embryos were determined using a dissection
microscope (Leica MZ16F) equipped with color camera (Leica DFC420). For P2 or
later pups, eye pigmentation and coat color were visually assessed.
SMRT sequencing and bioinformatics analysis. Harvested embryos were sub-
jected to whole-genome ampliﬁcation using the REPLI-g Single Cell Kit (Qiagen, Cat
No. 150343). A portion of the Tyr gene was ampliﬁed using the KOD Hot Start DNA
Polymerase (EMD Millipore, Cat. No. 71086) and puriﬁed using the QIAquick PCR
puriﬁcation kit (Qiagen, Cat No. 28106). Primer pairs used for PCR were uniquely
indexed for each embryo at the 5′ ends with 16-nucleotide asymmetric barcodes (see
Supplementary Figure 5a for complete primer set list). PCR products were pooled for
SMRTbell template preparation and sequenced using a PacBio RS II sequencer
following standard guidelines and procedures by the University of Massachusetts
Medical School, Deep Sequencing Core. Raw reads were processed by SMRT Ana-
lysis software (v2.3.0) pipelines to produce reads-of-inserts (ROIs) representing
multiplexed PCR amplicon sequences in fastq format. All downstream workﬂows
were performed using the Galaxy web-based platform for genome data analysis44–46,
unless speciﬁed. Reads were ﬁltered by length and demultiplexed. Sequences were
then aligned with BWA-MEM47 to a custom reference representing the unedited,
wild-type Tyr amplicon sequence. Imperfect alignments (deletions, insertions, and
mismatches) across the predicted edit site (−3nt of the PAM) were designated as
indel events. To determine the distribution of indel types due to Cas9 editing, only
full and intact reads that encompassed both asymmetric barcodes were considered
for analysis. Fasta formatted reads were clustered with USEARCH v8.1 sequence
analysis tools48. Speciﬁcally, identical sequences were tabulated with the -derep_-
fulllength command, followed by sequence clustering using operational taxonomic
units (OTUs) with the -cluster_otus command with the following options: -fulldp,
-otu_radius_pct 0.1, -minsize 5, -gapopen *I/1.0E, and -gapext *I/0.5E. Sequence
clusters were manually curated to group and count indel types. Unique indel types
were scored as a percentage of total reads.
DNA preparation for T7EI assay. GreenGo cells49 were co-transfected with
pAAV.U1a-SpCas9 and pAAVsc.U6-sgTyr.CB6-EGFP using Lipofectamine 3000
Transfection Reagent (Thermo Fisher Sci. Cat. No. L3000015). Three days later,
total DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Cat. No.
51306). Embryos cultured up to compacted morula or blastocyst stages were
harvested and subjected to whole-genome ampliﬁcation using the REPLI-g Single
Cell Kit (Qiagen, Cat. No. 150343). Whole E16.5 embryos were stored at −80 °C
until being powdered in liquid nitrogen. DNA was then extracted from tissue
powder using the Blood & Cell Culture DNA Maxi Kit (Qiagen, Cat. No. 13362).
T7EI nuclease assay. A portion of the Tyr gene or Fah gene was ampliﬁed using
the KOD Hot Start DNA Polymerase (EMD Millipore, Cat. No. 71086), puriﬁed
using the QIAquick PCR puriﬁcation kit (Qiagen, Cat. No. 28106), and subjected to
T7EI nuclease assay according to the manufacturer’s instruction (NEB, Cat. No.
M0302L). Digested products were resolved on a 2% agarose gel containing ethi-
dium bromide and imaged. Primers used for PCR are listed in Table 6.
TOPO sequencing. PCR products were puriﬁed using the QIAquick PCR Pur-
iﬁcation Kit (Qiagen, Cat. No. 28106). Puriﬁed PCR products were cloned into the
pCRTM-Blunt II-TOPO vector using Zero Blunt TOPO PCR Cloning Kit (Thermo
Fisher Sci. Cat. No. K280002), and used to transform DH5α Escherichia coli bac-
teria. Plasmid from individual colonies was extracted using the QIAcube auto-
mated sample preparation station (Qiagen), and subjected to Sanger sequencing.
Analysis of rAAV vector genome integration by standard PCR. DNA of tail
snips was used for PCR analysis. The same DNA samples were also used for PCR
and TOPO cloning and Sanger sequencing. The primer sequences are shown in
Table 6. PCR was carried out using the KOD Hot Start DNA Polymerase (EMD
Millipore, Cat. No. 71086), and ampliﬁed for 35 cycles. PCR products were
resolved on a 1% agarose gel containing ethidium bromide and imaged. A band of
predicted size (~450 bp) was excised and puriﬁed using the QIAquick Gel
Extraction Kit (Qiagen, Cat. No. 28706). Puriﬁed PCR product was cloned into the
pCRTM-Blunt II-TOPO vector using Zero Blunt TOPO PCR Cloning Kit (Thermo
Fisher Sci. Cat. No. K280002) and sequenced using the Sanger method.
Genome-wide rAAV vector integration analysis. DNA libraries for integration
proﬁling were generated by LAM-PCR and subjected to SMRT sequencing. The
overall protocol design was modiﬁed from the high-throughput, genome-wide,
translocation sequencing procedure50. Brieﬂy, whole-genomic DNAs were
extracted from snap-frozen and powdered tissues from experimental E16.5
embryos, and adult mouse liver treated with rAAV9-SpCas9 and rAAV9.U6-
sgAspa.CB6-EGFP as a positive control sample. Genomic material (20 μg total
input) was fragmented by TaqαI digestion (NEB, Cat. No. R0149M). Fragmented
DNAs were subjected to phenol–chloroform extraction and ethanol precipitation
to purify the fragmented material. Template DNAs were next subjected to 80 cycles
of LAM-PCR with KOD Hot Start DNA Polymerase and a biotinylated primer with
speciﬁcity to the rAAV-polyA sequence: 5′-/5Biosg/CTTGAGCATCT-
GACTTCTGGCTAATAAAGG-3′. Single-strand, biotinylated PCR products were
next captured on magnetic beads, enriched, and ligated to a bridge adapter by on-
bead ligation. Nested PCR (30 cycles) to generate SMRT sequencing libraries was
next carried out using asymmetrically barcoded forward and reverse primer sets:
Forward: 5′-XXXXXXXXXXXXXXXXAGGAACCCCTAGTGATGGAGT-3′
Reverse: 5′-XXXXXXXXXXXXXXXXACTATAGGGCACGCGTGGT-3′.
Individual libraries were then subjected to 0.6× AMPurePB bead (Paciﬁc
Biosciences, Cat. No. 100-265-900) puriﬁcation, pooled, and submitted for
standard SMRT sequencing analysis as described above. The resulting ROIs were
ﬁltered by barcode demultiplexing and screened for the presence of a 10-nt feature
that is unique to the rAAV-ITR (5′-TGGCCACTCC-3′). This ﬁltering method
ensures that non-speciﬁc ampliﬁcation products are not falsely identiﬁed as
integration events. The resulting positive reads were then mapped to the mm10
mouse genome using BWA-MEM47. Integration events were summarized using a
custom R-script (ggbio)51 to display as a karyogram.
Data availability. Sequencing data have been deposited in the NCBI sequence read
archive (SRA) under accession code 127366 . All other data are available from the
authors upon reasonable request.
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